CD79B Antibody (SN8/3A2-2E7): sc-80538

CD79B Antibody (SN8/3A2-2E7) is a mouse monoclonal IgG1 antibody that detects CD79B in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD79B, also known as B29, is a critical component of the B cell antigen receptor complex, functioning alongside CD79A to facilitate the signaling necessary for B cell activation and development. CD79B (SN8/3A2-2E7) antibody recognizes a protein containing a cytoplasmic tail with an immuno-receptor tyrosine-based activation motif (ITAM) that is essential for initiating downstream signaling cascades upon antigen binding. This activation is crucial for B cell proliferation, differentiation, and the production of antibodies, making CD79B a vital player in adaptive immunity. Furthermore, the interaction of CD79B with membrane immunoglobulins, such as IgM and IgD, is fundamental for their surface expression and antigen presentation capabilities, underscoring CD79B′s significance in maintaining effective immune surveillance and response. Anti-CD79B antibody (SN8/3A2-2E7) serves as an invaluable tool for researchers studying B cell biology and the mechanisms underlying immune responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD79B Antibody (SN8/3A2-2E7) References:

1. Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition.  |  Kouro, T., et al. 2001. Int Immunol. 13: 485-93. PMID: 11282988
2. SDF-1alpha regulates HIV-1-gp120-induced changes in CD79b surface expression and Ig production in activated human B cells.  |  Nance, CL. and Shearer, WT. 2002. Clin Immunol. 105: 208-14. PMID: 12482395
3. Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation.  |  Fuentes-Pananá, EM., et al. 2006. J Immunol. 177: 7913-22. PMID: 17114463
4. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.  |  Zheng, B., et al. 2009. Mol Cancer Ther. 8: 2937-46. PMID: 19808977
5. Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas.  |  Capello, D., et al. 2011. Br J Haematol. 152: 777-80. PMID: 21275949
6. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.  |  Cao, XX., et al. 2017. Ann Hematol. 96: 1867-1871. PMID: 28803429
7. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.  |  Zheng, M., et al. 2017. Neuropathology. 37: 509-516. PMID: 28856744
8. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.  |  Aggarwal, V., et al. 2019. Appl Immunohistochem Mol Morphol. 27: 311-318. PMID: 29734251
9. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.  |  Chen, Z., et al. 2020. Am J Surg Pathol. 44: 444-455. PMID: 31609782
10. Prevalence and prognostic value of MYD88 and CD79B mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.  |  Kirkegaard, MK., et al. 2023. Br J Ophthalmol. 107: 576-581. PMID: 34706861

The preferred CD79B antibody is CD79B Antibody (B29/123): sc-53210.